IL-8 受体修饰的 CD70 CAR T 细胞治疗 CD70+ 和 MGMT 未甲基化成人胶质母细胞瘤 (IMPACT) 的 I 期研究 (IMPACT)
I 期研究——评估 IL-8 受体修饰的患者来源的活化 CD70 CAR T 细胞治疗 CD70+ 和 MGMT 未甲基化成人 GBM 的安全性和可行性
This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in CD70+ adult glioblastoma
研究概览
地位
详细说明
Newly diagnosed CD70 positive adult GBM patients who have undergone surgery for maximal debulking will be enrolled in this 3+3 design dose-escalation clinical trial and undergo peripheral venipuncture for collection of PBMCs for generation of investigational 8R-70CAR T Cell vaccine. Patients will then undergo standard of care chemoradiation. Immunotherapy will begin 2 weeks (-7/+4 days) after completion of radiation. One single dose of 8R-70CAR T cells will be administered IV. The dose will depend on the enrolling cohort. Dose escalation will follow the traditional 3+3 design.
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Florida
-
Gainesville、Florida、美国、32608
- University of Florida Health
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria (Adult GBM):
- Age ≥ 18 years
- Newly-diagnosed de novo GBM based on the absence of previous history of brain tumor (WHO Grade IV glioma) by histopathology or molecular studies. (secondary GBM not eligible)
- The tumor must have a supratentorial component
- CD70 positive (≥5%, 1+)
Tumor expression will be scored on a scale of 0 to 3 staining intensity:
0 = Negative
-
= Low level
-
= Moderate level
-
= High level
-
The criteria for inclusion will be at least 5% of the cells scoring 1+ staining intensity (> 5%, 1+).
- Surgical resection of tumors with less than 3cm x 3cm (9 cm2) residual enhancing tumor as a product of longest perpendicular planes by MRI or biopsy only for tumor measuring less than 3cm x 3cm
- Karnofsky Performance Status (KPS) of > 70%
- CBC with differential with adequate bone marrow function as defined below:
-
Absolute neutrophil count (ANC) ≥ 1500 cells/mm3.
-
Platelet count ≥ 100,000 cells/mm3.
-
Hemoglobin ≥ 10 g/dl. (The use of transfusion or other intervention to achieve Hgb ≥ 10 g/dl is acceptable.)
• Adequate renal function as defined below:
-
BUN ≤ 25 mg/dl
-
Creatinine ≤ 1.7 mg/dl
• Adequate hepatic function as defined below:
-
Bilirubin ≤ 2.0 mg/dl
-
ALT ≤ 5 times institutional upper limits of normal for age
-
AST ≤ 5 times institutional upper limits of normal for age
- Signed informed consent. If the patient's mental status precludes his/her giving informed consent, written informed consent may be given by the legally authorized representative.
- For females of childbearing potential, a negative serum pregnancy test at enrollment.
- Women of childbearing potential (WOCBP) must be willing to use an acceptable contraceptive method to avoid pregnancy throughout the study and for at least 24 weeks after the last dose of study drug.
- Males with female partners of childbearing potential must agree to practice adequate contraceptive methods throughout the study and should avoid conceiving children for 24 weeks following the last dose of study drug.
-
Exclusion Criteria (Adult GBM):
- Prior invasive malignancy (except for non-melanomatous skin cancer) unless disease free for ≥ 3years. (In situ cancer are permissible)
- Metastases detected below the tentorium or beyond the cranial vault
- Leptomeningeal disease beyond the cranial vault. (Focal, adjacent and leptomeningeal involvement is allowable at the discretion of the PI).
- Recurrent or multifocal malignant gliomas.
- The patient is not a candidate for cellular therapy as assessed by the study bone marrow transplant physician.
- Known immunosuppressive disease or human immunodeficiency virus (HIV) infection.
Rationale: The need to exclude patients with the immunosuppressive disease or human
-
Severe, active co-morbidity, defined as follows:
- Unstable angina and/or congestive heart failure requiring hospitalization.
- Transmural myocardial infarction within the last 6 months.
- Acute bacterial or fungal infection requiring intravenous antibiotics at the initiation of XRT/TMZ.
- Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the initiation of XRT/TMZ.
- Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects.
- Patients with an autoimmune disease requiring medical management with immunosuppressants.
- Major medical illnesses or psychiatric impairments that, in the investigator's opinion, will prevent administration or completion of protocol therapy.
- Active connective tissue disorders such as lupus or scleroderma that, in the investigator's opinion, place the patient at high risk for radiation toxicity.
-
Pregnant or lactating women, due to possible adverse effects on the developing fetus or infant.
-
Patients treated on any other therapeutic clinical protocols within 30 days prior to enrollment.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:8R-70CAR T cells
Cohort 1 will receive 1 x 10^6 cells/kg. Cohort 2 will receive 1 x 10^7 cells/kg. Cohort 3 will receive 1 x 10^8 cells/kg. Cohort 4 will receive Cy/Flu + CAR T cells at established maximum tolerated dose. |
Single dose of 8R-70CAR T cells administered IV
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety of 8R-70CAR T-cell therapy in adult patients with de novo CD70+ GBM
大体时间:28 days post-infusion
|
Defined as ≤ 1 DLT out of 6 patients is observed at the 1x10^8 cells/Kg dose. Dose-Limiting toxicity (DLT) will be defined as any adverse event attributable (possible, probable, or definite) to the administration of 8R-70CAR T cells and occurring from the time of infusion through 28 days post-infusion. |
28 days post-infusion
|
|
Feasibility of 8R-70CAR T-cell therapy in adult patients with de novo CD70+ GBM
大体时间:10 weeks
|
Feasibility will be defined as the ability to infuse 8R-70CAR T-cell safely in 66.7 % of enrolled patients (patients who signed consent and were deemed eligible for the study). |
10 weeks
|
合作者和调查者
调查人员
- 首席研究员:Ashley Ghiaseddin, MD、University of Florida
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- IRB202200057-A
- OCR41673 (其他标识符:University of Florida)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.